<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740165</url>
  </required_header>
  <id_info>
    <org_study_id>7339-001</org_study_id>
    <secondary_id>2018-001973-25</secondary_id>
    <secondary_id>ENGOT-ov43</secondary_id>
    <secondary_id>MK-7339-001</secondary_id>
    <secondary_id>KEYLYNK-001</secondary_id>
    <secondary_id>194619</secondary_id>
    <secondary_id>GOG-3036</secondary_id>
    <nct_id>NCT03740165</nct_id>
  </id_info>
  <brief_title>Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43)</brief_title>
  <official_title>A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001/ENGOT-ov43)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Network for Gynaecological Oncological Trial Groups</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of treatment with
      carboplatin/paclitaxel PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in
      women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal
      cancer.

      The primary study hypotheses are that the combination of pembrolizumab plus
      carboplatin/paclitaxel followed by continued pembrolizumab and maintenance olaparib is
      superior to carboplatin/paclitaxel alone with respect to Progression Free Survival (PFS) per
      Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) and/or Overall Survival
      (OS), and that the combination of pembrolizumab plus carboplatin/paclitaxel followed by
      continued pembrolizumab is superior to carboplatin/paclitaxel alone with respect to PFS per
      RECIST 1.1 and/or OS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a lead-in period during which all participants receive a single 3-week cycle of
      carboplatin/paclitaxel, participants will be randomly assigned in to one of three treatment
      arms:

        -  Pembrolizumab+Olaparib,

        -  Pembrolizumab+Placebo for Olaparib, or

        -  Placebo for Pembrolizumab+Placebo for Olaparib.

      At Investigator's discretion and prior to participant randomization, one of the following
      carboplatin/paclitaxel regimens is to be selected:

        1. up to 5 cycles of carboplatin Area Under the Curve (AUC)5 or AUC6 AND paclitaxel 175
           mg/m^2 on Day 1 of each 3-week cycle

        2. up to 5 cycles of carboplatin AUC5 or AUC6 on Day 1 of each 3-week cycle AND paclitaxel
           80 mg/m^2 on Days 1, 8 and 15 of each 3-week cycle; or

        3. up to 5 cycles of carboplatin AUC2 or AUC2.7 AND paclitaxel 60 mg/m^2 on Days 1, 8 and
           15 of each 3-week cycle.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2018</start_date>
  <completion_date type="Anticipated">August 8, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 8, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on Investigator assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by the Investigator will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>OS is defined as the time from the date of randomization to death due to any cause. The OS will be presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS Per RECIST 1.1 As Assessed by Blinded Independent Central Review</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by blinded independent central review will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS After Next-line Treatment (PFS2) Following Discontinuation of Study Treatment As Assessed by the Investigator</measure>
    <time_frame>Up to approximately 78 months</time_frame>
    <description>PFS2 is defined as the time from randomization until PD on next-line treatment or death due to any cause, whichever occurs first. The PFS2 per Investigator assessment will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 73 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinue Study Treatment Due to an AE</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>The number of participants who discontinue study treatment due to an AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Global Health Status/Quality of Life (GHS/QoL) Score Using Questions from the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30)</measure>
    <time_frame>Baseline and End of Study Participation (Up to approximately 6 years)</time_frame>
    <description>Participants are asked to answer 2 questions from the EORTC QLQ-C30 about their GHS: &quot;How would you rate your overall health during the past week?&quot; and &quot;How would you rate your overall quality of life during the past week?&quot; Responses are based on a 7-point scale (1=Very poor; 7=Excellent), with a higher score indicating a better global health status. The change from baseline in GHS/QoL score of participants will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Abdominal and Gastrointestinal (Abdominal/GI) Symptoms Score Using the EORTC Quality of Life Questionnaire-Ovarian Cancer (QLQ-OV28) Abdominal/GI Symptom Scale</measure>
    <time_frame>Baseline and End of Study Participation (Up to approximately 6 years)</time_frame>
    <description>Participants are asked to answer 6 questions from the EORTC QoL Questionnaire-Ovarian Cancer (QLQ-OV28) abdominal/GI symptom scale about abdominal pain, bloated feeling in abdomen/stomach, changes in clothing fit, changes in bowel habit, flatulence and stomach fullness when eating. Responses are based on a 4-point scale (1=Not at all; 4=Very much), with a lower score indicating better abdominal/GI symptoms. The change from baseline in abdominal/GI symptom score of participants will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Subsequent Anti-cancer Treatment (TFST)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>TFST is defined as the time from randomization to initiation of first subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TFST will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Second Subsequent Anti-cancer Treatment (TSST)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>TSST is defined as the time from randomization to initiation of second subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TSST will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discontinuation of Study Treatment or Death (TDT)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>TDT is defined as the time from the date of randomization to discontinuation of study treatment or death due to any cause, whichever occurs first. The TDT will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological Complete Response (pCR) Rate</measure>
    <time_frame>Up to approximately 30 months</time_frame>
    <description>pCR is defined as all surgical specimens collected during the interval debulking surgery are microscopically negative for malignancy. The pCR rate for all surgical specimens will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Without Symptom of Disease Progression or Toxicity of Treatment (TWiST)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>TWiST is defined as the time from randomization to disease progression or treatment-related toxicity, whichever occurs first. The TWiST will be presented.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1086</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab+Olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive carboplatin/paclitaxel via intravenous (IV) infusion for five 3-week cycles PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS olaparib 300 mg via oral tablet twice each day (BID), starting with Cycle 7. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab+Placebo for Olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles starting in Cycle 1 PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Pembrolizumab+Placebo for Olaparib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles PLUS placebo for pembrolizumab (normal saline or dextrose) via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+Olaparib</arm_group_label>
    <arm_group_label>Pembrolizumab+Placebo for Olaparib</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo for Pembrolizumab+Placebo for Olaparib</arm_group_label>
    <other_name>normal saline or dextrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+Olaparib</arm_group_label>
    <arm_group_label>Pembrolizumab+Placebo for Olaparib</arm_group_label>
    <arm_group_label>Placebo for Pembrolizumab+Placebo for Olaparib</arm_group_label>
    <other_name>PARAPLATIN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+Olaparib</arm_group_label>
    <arm_group_label>Pembrolizumab+Placebo for Olaparib</arm_group_label>
    <arm_group_label>Placebo for Pembrolizumab+Placebo for Olaparib</arm_group_label>
    <other_name>TAXOL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Pembrolizumab+Olaparib</arm_group_label>
    <other_name>MK-7339</other_name>
    <other_name>LYNPARZA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for olaparib</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Pembrolizumab+Placebo for Olaparib</arm_group_label>
    <arm_group_label>Placebo for Pembrolizumab+Placebo for Olaparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+Olaparib</arm_group_label>
    <arm_group_label>Pembrolizumab+Placebo for Olaparib</arm_group_label>
    <arm_group_label>Placebo for Pembrolizumab+Placebo for Olaparib</arm_group_label>
    <other_name>AVASTIN®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has histologically confirmed International Federation of Gynecology and Obstetrics
             (FIGO) Stage III or Stage IV EOC (high-grade predominantly serous, endometrioid,
             carcinosarcoma, mixed mullerian with high-grade serous component, clear cell, or
             low-grade serous OC), primary peritoneal cancer, or fallopian tube cancer

          -  Has just completed primary debulking surgery or is eligible for primary or interval
             debulking surgery

          -  Is a candidate for carboplatin and paclitaxel chemotherapy, to be administered in the
             adjuvant or neoadjuvant setting

          -  Candidates for neoadjuvant chemotherapy, has a cancer antigen 125 (CA-125)
             (kilounits/L):carcinoembryonic antigen (CEA; ng/mL) ratio greater than or equal to 25

          -  Is able to provide a newly obtained core or excisional biopsy of a tumor lesion for
             prospective testing of BRCA1/2 and Programmed Cell Death-Ligand 1 (PD-L1) tumor
             markers status prior to randomization

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as
             assessed within 7 days prior to initiating chemotherapy in the lead-in period and
             within 7 days prior to randomization

          -  Is not pregnant, not breastfeeding, and 1 of the following conditions applies: a.) Not
             a woman of childbearing potential (WOCBP) OR b.) A WOCBP who agrees to follow
             contraceptive guidance during the treatment period and for at least 120 days following
             the last dose of pembrolizumab (or pembrolizumab placebo) and olaparib (or olaparib
             placebo) and at least 210 days following the last dose of chemotherapy or bevacizumab
             (if administered)

          -  Has adequate organ function

        Exclusion Criteria:

          -  Has mucinous, germ cell, or borderline tumor of the ovary

          -  Has a known or suspected deleterious mutation (germline or somatic) in either BRCA1 or
             BRCA2

          -  Has a history of non-infectious pneumonitis that required treatment with steroids or
             currently has pneumonitis

          -  Has either myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or has features
             suggestive of MDS/AML

          -  Has a known additional malignancy that is progressing or has required active treatment
             in the last 3 years Note: Participants with basal cell carcinoma of the skin, squamous
             cell carcinoma of the skin, or carcinoma in situ (e.g. ductal carcinoma in situ,
             cervical carcinoma in situ) that has undergone potentially curative therapy are not
             excluded.

          -  Has ongoing Grade 3 or Grade 4 toxicity, excluding alopecia, following chemotherapy
             administered during the lead-in period

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (dosing &gt;10 mg daily of prednisone equivalent) or any other form of immunosuppressive
             therapy within 7 days prior to randomization

          -  Has an active autoimmune disease that has required systemic treatment in the past 2
             years (i.e., with use of disease modifying agents, corticosteroids or
             immunosuppressive drugs) Note: Replacement therapy (e.g. thyroxine, insulin, or
             physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency)
             is not considered a form of systemic treatment and is allowed.

          -  Has a known history of active tuberculosis (TB; Bacillus Tuberculosis)

          -  Has an active infection requiring systemic therapy

          -  Has received colony-stimulating factors (eg, granulocyte colony stimulating factor
             [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF] or recombinant
             erythropoietin) within 4 weeks prior to receiving chemotherapy during the lead-in
             period

          -  Is considered to be of poor medical risk due to a serious, uncontrolled medical
             disorder, non-malignant systemic disease or active, uncontrolled infection

          -  Has had surgery to treat borderline tumors, early stage EOC, or fallopian tube cancer
             &lt;6 months prior to screening

          -  Has a known history of human immunodeficiency virus (HIV) infection

          -  Has a known history of hepatitis B virus (HBV) or known active hepatitis C virus (HCV)
             infection

          -  Is either unable to swallow orally administered medication or has a gastrointestinal
             (GI) disorder affecting absorption (e.g. gastrectomy, partial bowel obstruction,
             malabsorption)

          -  Has uncontrolled hypertension, defined as defined as systolic &gt;140 mm Hg or diastolic
             &gt;90 mm Hg documented by 2 blood pressure readings taken at least 1 hour apart. Note:
             This applies to participants who will receive bevacizumab. Use of antihypertensive
             medications to control blood pressure is allowed.

          -  Has current, clinically relevant bowel obstruction (including sub-occlusive disease),
             abdominal fistula or GI perforation, related to underlying EOC (for participants
             receiving bevacizumab)

          -  Has a history of hemorrhage, hemoptysis or active GI bleeding within 6 months prior to
             randomization (for participants receiving bevacizumab)

          -  Is a WOCBP who has a positive urine pregnancy test within 72 hours before the first
             dose of chemotherapy in the lead-in period and within 72 hours prior to randomization,
             is pregnant or breastfeeding, or is expecting to conceive children within the
             projected duration of the study, starting with screening through 120 days following
             the last dose of pembrolizumab (or pembrolizumab placebo) and olaparib (or olaparib
             placebo) and at least 210 days following the last dose of chemotherapy or bevacizumab
             (if administered)

          -  Has received prior treatment for advanced or metastatic OC, including radiation or
             systemic anti-cancer therapy (e.g. chemotherapy, hormonal therapy, immunotherapy,
             investigational therapy)

          -  Has received prior therapy with an anti-Programmed Cell Death-1 (anti-PD-1),
             anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or
             co-inhibitory T-cell receptor (e.g. cytotoxic T lymphocyte antigen-4 [CTLA-4], OX 40,
             CD137)

          -  Has received prior therapy with either olaparib or any other poly(adenosine-ribose)
             polymerase (PARP) inhibitor

          -  Has intraperitoneal chemotherapy planned or has been administered as first-line
             therapy

          -  Has received a live vaccine within 30 days prior to the first dose of study treatment

          -  Has severe hypersensitivity (≥Grade 3) to pembrolizumab, olaparib, carboplatin,
             paclitaxel or bevacizumab (if using) and/or any of their excipients

          -  Is currently receiving either strong (e.g. itraconazole, telithromycin,
             clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir,
             saquinavir, nelfinavir, boceprevir, telaprevir) or moderate (eg, ciprofloxacin,
             erythromycin, diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450
             (CYP)3A4 that cannot be discontinued for the duration of the study

          -  Is currently receiving either strong (e.g. phenobarbital, enzalutamide, phenytoin,
             rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine, and St John's Wort) or
             moderate (e.g. bosentan, efavirenz, modafinil) inducers of CYP3A4 that cannot be
             discontinued for the duration of the study

          -  Has received whole blood transfusions in the last 120 days prior to randomization

          -  Is currently participating or has participated in a study of an investigational agent
             or has used an investigational device within 4 weeks of the first dose of study
             treatment

          -  Has resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible
             cardiac conditions or participant has congenital long QT syndrome

          -  Has had an allogenic tissue/solid organ transplant, has received previous allogenic
             bone-marrow transplant, or has received double umbilical cord transplantation

          -  Either has had major surgery within 2 weeks of randomization or has not recovered from
             any effects of any major surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Disney Family Cancer Center ( Site 0042)</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>818-748-4723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oncology Clinical Trial -Oakland ( Site 0077)</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>707-651-2797</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oncology Clinical Trial - San Francisco ( Site 0078)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>707-651-2797</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oncology Clinical Trial - Santa Clara ( Site 0079)</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>707-651-2797</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente N. CA Regional Oncology Clinical Trials ( Site 0008)</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>707-651-2797</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oncology Clinical Trial - Walnut Creek ( Site 0080)</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>707-651-2797</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital ( Site 0023)</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>941-917-6519</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University ( Site 0053)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-1013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-778-1900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Physicians Group ( Site 0029)</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>770-219-8822</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Health University Medical Center ( Site 0011)</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>912-350-7878</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago ( Site 0049)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-702-6721</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Sudarshan K. Sharma, LTD ( Site 0061)</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>630-601-7719</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital and Health Center ( Site 0012)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>317-415-6747</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital and Clinics ( Site 0005)</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>319-356-2015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky ( Site 0045)</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>859-257-4021</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weinberg Cancer Institute at Franklin Square ( Site 0035)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>443-777-7364</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Dominic - Jackson Memorial Hospital ( Site 0072)</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>601-200-4970</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University - School of Medicine ( Site 0062)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-362-1740</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital ( Site 0063)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>402-354-8250</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center ( Site 0037)</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>201-541-6384</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital [Dayton, OH] ( Site 0073)</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>937-438-7819</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Bing Cancer Center ( Site 0044)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>614-488-2118</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OSU Wexner Medical Center ( Site 0076)</name>
      <address>
        <city>Hilliard</city>
        <state>Ohio</state>
        <zip>43026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>614-366-9227</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital [Providence, RI] ( Site 0039)</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>401-453-7520</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Gynecology Oncology ( Site 0004)</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>605-312-3324</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center ( Site 0046)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-648-7097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin- Milwaukee ( Site 0064)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>414-805-6647</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George Hospital ( Site 2207)</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61291133461</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cairns and Hinterland Hospital and Health Service ( Site 2201)</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61742268085</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ballarat Health Services ( Site 2202)</name>
      <address>
        <city>Ballarat</city>
        <state>Victoria</state>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61353204000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Health ( Site 2204)</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6185722024</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital. ( Site 2205)</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61404450141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis Bonheiden ( Site 0301)</name>
      <address>
        <city>Bonheiden</city>
        <state>Antwerpen</state>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3215504625</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc ( Site 0312)</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-Capitale, Region De</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3227645471</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi ( Site 0302)</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3271104762</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis ( Site 0309)</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3211337960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Ardenne ( Site 0303)</name>
      <address>
        <city>Libramont</city>
        <state>Luxembourg</state>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3261238111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares Gent ( Site 0300)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3292469522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent ( Site 0307)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3293320341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Campus Gasthuisberg ( Site 0306)</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3216347419</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Liege ( Site 0310)</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3243679519</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto do Cancer do Ceara ( Site 2707)</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceara</state>
        <zip>60430-230</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+558532884576</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Araujo Jorge Associacao de Combate ao Cancer de Goias ( Site 2708)</name>
      <address>
        <city>Goiania</city>
        <state>Goias</state>
        <zip>74605-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+556232437260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Caridade de Ijui ( Site 2712)</name>
      <address>
        <city>Ijui</city>
        <state>Rio Grande Do Sul</state>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555533319393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Bruno Born ( Site 2704)</name>
      <address>
        <city>Lajeado</city>
        <state>Rio Grande Do Sul</state>
        <zip>95900-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5551371475002476</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora Da Conceicao ( Site 2703)</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555133572092</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancer Hospital do Cancer II ( Site 2700)</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20220-410</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+552132076507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 2714)</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+551138932686</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica de Pesquisas e Ctro de Estudos Onc. Ginecol. e Mamaria Ltda ( Site 2706)</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01317-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>11991931500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 2710)</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01321-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+551135056675</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre ( Site 0200)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4039190251</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre ( Site 0207)</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61354966666694</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Credit Valley Hospital ( Site 0206)</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9058134759</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital.. ( Site 0202)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4169464501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS du Saguenay-Lac-St-Jean ( Site 0218)</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>41854110002707</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0219)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>51425234005853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0208)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514890800030657</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital McGill University Health Centre ( Site 0211)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514934193431975</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 2808)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4810218</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56957983173</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedad de Investigaciones Medicas Limitadas ( Site 2810)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56452982404</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Arturo Lopez Perez FALP ( Site 2800)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>7500921</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sociedad Oncovida S.A. ( Site 2807)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>7510032</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56998634501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iram Cancer Research ( Site 2809)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>7630370</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56931912746</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile ( Site 2805)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8330032</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56223547919</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncocentro ( Site 2801)</name>
      <address>
        <city>Vina del Mar</city>
        <state>Valparaiso</state>
        <zip>2520598</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56992369820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Antofagasta ( Site 2804)</name>
      <address>
        <city>Antofagasta</city>
        <zip>1240000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56994198125</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Biomelab S A S ( Site 2900)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 2913)</name>
      <address>
        <city>Valledupar</city>
        <state>Cesar</state>
        <zip>200002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573128385292</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncomedica S.A. ( Site 2911)</name>
      <address>
        <city>Monteria</city>
        <state>Cordoba</state>
        <zip>230002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573164106262</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 2912)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>111321</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573176447300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia E.S.E ( Site 2910)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>111511</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573102013510</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico Imbanaco de Cali S.A ( Site 2909)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>572682100014091</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hemato Oncologos S.A. ( Site 2906)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573013522326</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno ( Site 0404)</name>
      <address>
        <city>Brno</city>
        <state>Brno-mesto</state>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420532233843</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava ( Site 0403)</name>
      <address>
        <city>Ostrava-Poruba</city>
        <state>Moravskoslezsky Kraj</state>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420597371825</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze ( Site 0400)</name>
      <address>
        <city>Praha</city>
        <state>Praha, Hlavni Mesto</state>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420224967451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Bulovce ( Site 0401)</name>
      <address>
        <city>Praha</city>
        <state>Praha, Hlavni Mesto</state>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420266083202</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc ( Site 0402)</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420588444288</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Prive Jean Mermoz ( Site 0607)</name>
      <address>
        <city>Lyon</city>
        <state>Auvergne</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33478782888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss ( Site 0615)</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33388252485</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Brest -Site Hopital Morvan ( Site 0616)</name>
      <address>
        <city>Brest</city>
        <state>Finistere</state>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33298223451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie du Gard - CHU Caremeau ( Site 0610)</name>
      <address>
        <city>Nimes</city>
        <state>Gard</state>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33430061010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Lucien Neuwirth ( Site 0613)</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <state>Loire</state>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+334779176034</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre D Oncologie de Gentilly ( Site 0609)</name>
      <address>
        <city>Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33383935005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy ( Site 0600)</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3342114211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon ( Site 0612)</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33156016628</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen ( Site 0718)</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492418037031</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Krefeld ( Site 0715)</name>
      <address>
        <city>Krefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49 2151 32 2969</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caritas Klinikum Saarbruecken St. Theresia ( Site 0702)</name>
      <address>
        <city>Saarbruecken</city>
        <state>Saarland</state>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+496814061301</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Krankenhaus Kiel GmbH ( Site 0709)</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4943116971704</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 0805)</name>
      <address>
        <city>Pecs</city>
        <state>Baranya</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3672536370</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz ( Site 0802)</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36302780644</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet ( Site 0800)</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36309313155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uzsoki Utcai Korhaz ( Site 0803)</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3614673776</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 0801)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209216022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center ( Site 1006)</name>
      <address>
        <city>Beer-Sheva</city>
        <state>HaDarom</state>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97286244068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 1004)</name>
      <address>
        <city>Petah Tikva</city>
        <state>HaMerkaz</state>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239377428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center ( Site 1011)</name>
      <address>
        <city>Hadera</city>
        <state>Heifa</state>
        <zip>3810101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97246304335</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center ( Site 1007)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97248250336</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 1002)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247771784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center ( Site 1003)</name>
      <address>
        <city>Holon</city>
        <state>Tell Abib</state>
        <zip>5822012</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235028795</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center ( Site 1000)</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tell Abib</state>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235303157</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center ( Site 1001)</name>
      <address>
        <city>Tel Aviv</city>
        <state>Tell Abib</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236973494</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center ( Site 1005)</name>
      <address>
        <city>Jerusalem</city>
        <state>Yerushalayim</state>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226555727</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 1108)</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390805555420</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sacro Cuore di Gesu Fatebenefratelli ( Site 1112)</name>
      <address>
        <city>Benevento</city>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390824771246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Cannizzaro ( Site 1110)</name>
      <address>
        <city>Catania</city>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390957262274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Lecco. Ospedale A. Manzoni ( Site 1101)</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39341489155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia ( Site 1100)</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390257489543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Federico II di Napoli ( Site 1107)</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390817464272</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IRCCS Universita degli Studi di Padova ( Site 1113)</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390498215931</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico Umberto I ( Site 1111)</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390649972535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Gemelli ( Site 1105)</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390630154994</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Citta della Salute e della Scienza di Torino ( Site 1104)</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390113134428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Santa Chiara ( Site 1109)</name>
      <address>
        <city>Trento</city>
        <zip>38122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390461902121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Univ. S. M. della Misericordia ( Site 1114)</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390432559330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East ( Site 2602)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81471331111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center ( Site 2601)</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81899991111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital ( Site 2600)</name>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81899645111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gunma Prefectural Cancer Center ( Site 2609)</name>
      <address>
        <city>Ota</city>
        <state>Gunma</state>
        <zip>373-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81276380771</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital ( Site 2607)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81117161161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital ( Site 2606)</name>
      <address>
        <city>Shiwa-gun</city>
        <state>Iwate</state>
        <zip>028-3695</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81196137111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine Hospital ( Site 2613)</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81449778111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of the Ryukyus Hospital ( Site 2616)</name>
      <address>
        <city>Nakagami-gun</city>
        <state>Okinawa</state>
        <zip>903-0215</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81988953331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University International Medical Center ( Site 2604)</name>
      <address>
        <city>Hidaka</city>
        <state>Saitama</state>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81429844111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center ( Site 2614)</name>
      <address>
        <city>Kitaadachi-gun</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81487221111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Defense Medical College Hospital ( Site 2608)</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <zip>359-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81429951511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital ( Site 2610)</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81422475511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kagoshima City Hospital ( Site 2612)</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8760</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81992307000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital ( Site 2618)</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81252665111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute ( Site 2617)</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81669451181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital ( Site 2605)</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335422511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 2404)</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82317877253</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 2403)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220724863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 2400)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222282246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 2402)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230103640</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 2401)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82234103513</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1404)</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48225462295</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bialostockie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 1412)</name>
      <address>
        <city>Bialystok</city>
        <state>Podlaskie</state>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48856656732</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpitale Pomorskie Sp. z o.o. ( Site 1407)</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48587260156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1406)</name>
      <address>
        <city>Gliwice</city>
        <state>Slaskie</state>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48322788613</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swietokrzyskie Centrum Onkologii SPZOZ ( Site 1410)</name>
      <address>
        <city>Kielce</city>
        <state>Swietokrzyskie</state>
        <zip>25-734</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48413674357</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Panskiego ( Site 1401)</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48618549014</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Clinical Oncological Dispensary ( Site 1508)</name>
      <address>
        <city>Arkhangelsk</city>
        <state>Arkhangelskaya Oblast</state>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78182275913</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1507)</name>
      <address>
        <city>Ufa</city>
        <state>Baskortostan, Respublika</state>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A. Tsyb Medical Radiological Research Center ( Site 1513)</name>
      <address>
        <city>Obninsk</city>
        <state>Kaluzskaja Oblast'</state>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79107070109</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBI National Medical Oncology Research Center n.a. N.N. Blokhina ( Site 1500)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79036787205</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSCC of Special Types of Med. Care and Technologies ( Site 1503)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74953956197</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Rehabilitation Center ( Site 1502)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79264375889</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Clinical Oncology Center ( Site 1505)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78129351330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 1504)</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219464788</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1509)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79172662851</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Care Langenhoven Drive Oncology Centre ( Site 1701)</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27414506154</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sandton Oncology Medical Group PTY LTD ( Site 1712)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27118830900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research ( Site 1702)</name>
      <address>
        <city>Parktown-Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27113390620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology ( Site 1703)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27123541054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilgers Oncology Centre ( Site 1705)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0081</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27128072744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Curo Oncology ( Site 1710)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27123356771</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Little Company of Mary Hospital ( Site 1700)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27123466701</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Oncology Centre ( Site 1709)</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27312088666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancercare ( Site 1706)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27219443700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital ( Site 1704)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27214044263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Outeniqua Cancercare Oncology Unit ( Site 1708)</name>
      <address>
        <city>George</city>
        <state>Western Cape</state>
        <zip>6530</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27413630581</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cape Town Oncology Trials Pty Ltd ( Site 1707)</name>
      <address>
        <city>Kraaifontein</city>
        <state>Western Cape</state>
        <zip>7570</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27219443830</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruna. CHUAC ( Site 1608)</name>
      <address>
        <city>A Coruna</city>
        <state>A Coruna [La Coruna]</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34981178000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 1603)</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08909</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932607333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xarxa Assistencial Universitaria Manresa ( Site 1605)</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+349387593005512</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Terrassa ( Site 1606)</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34937003612</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia ( Site 1602)</name>
      <address>
        <city>Donostia</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34943006032</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti ( Site 1609)</name>
      <address>
        <city>Lugo</city>
        <state>Lugo [Lugo]</state>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34982295112</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologia ( Site 1601)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961114013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia ( Site 1610)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34963187527</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial San Pedro de Alcantara ( Site 1607)</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34927621612</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra ( Site 1600)</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+349135319207513</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio ( Site 1604)</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34955013068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital ( Site 2507)</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886917154085</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital ( Site 2506)</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886422052121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital ( Site 2510)</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886423592525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 2508)</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88662353535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 2502)</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886972651480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MacKay Memorial Hospital ( Site 2500)</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886975835334</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital ( Site 2503)</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886912039453</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital ( Site 2501)</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>886975365883</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Etlik Zubeyde Hanım Gynecology Research Hospital ( Site 1903)</name>
      <address>
        <city>Ankara</city>
        <state>Adana</state>
        <zip>06050</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905327933357</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Acibadem University Atakent Hospital ( Site 1902)</name>
      <address>
        <city>Kucukcekmece</city>
        <state>İstanbul</state>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905323135566</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara UTF Cebeci Arastırma ve Uygulama Hastanesi ( Site 1905)</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905323633030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akdeniz Universitesi Tıp Fakultesi ( Site 1901)</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905424327513</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uludag Universitesi Tip Fakultesi ( Site 1904)</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905323739469</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Istanbul Tip Fakultesi ( Site 1900)</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905325637597</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bakirkoy Sadi Konuk Egitim ve Arastirma Hastanesi ( Site 1907)</name>
      <address>
        <city>Istanbul</city>
        <zip>34147</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905052703550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sakarya Universitesi Tip Fakultesi Hastanesi ( Site 1906)</name>
      <address>
        <city>Sakarya</city>
        <zip>54290</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322168074</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Precarpathian Clinical Oncology Center ( Site 2181)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380342502269</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 2180)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380956622833</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Khmelnytskyi Regional Hospital ( Site 2190)</name>
      <address>
        <city>Khmelnitskiy</city>
        <state>Khmelnytska Oblast</state>
        <zip>29000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380979242755</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncological Center ( Site 2140)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503818536</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2170)</name>
      <address>
        <city>Lviv</city>
        <state>Lvivska Oblast</state>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380677479407</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Odessa Regional Oncological Centre ( Site 2121)</name>
      <address>
        <city>Odesa</city>
        <state>Odeska Oblast</state>
        <zip>65055</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380487202605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>RMI - Sumy Regional Clinical Oncology Dispensary ( Site 2191)</name>
      <address>
        <city>Sumy</city>
        <state>Sumska Oblast</state>
        <zip>40022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380509158586</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central City Clinical Hospital ( Site 2150)</name>
      <address>
        <city>Uzhgorod</city>
        <state>Zakarpatska Oblast</state>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380505048997</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

